[go: up one dir, main page]

WO2003039480A3 - Methode de traitement de troubles lies a un taux de cholesterol eleve - Google Patents

Methode de traitement de troubles lies a un taux de cholesterol eleve Download PDF

Info

Publication number
WO2003039480A3
WO2003039480A3 PCT/US2002/035900 US0235900W WO03039480A3 WO 2003039480 A3 WO2003039480 A3 WO 2003039480A3 US 0235900 W US0235900 W US 0235900W WO 03039480 A3 WO03039480 A3 WO 03039480A3
Authority
WO
WIPO (PCT)
Prior art keywords
high cholesterol
treating
cholesterol concentration
disorder related
treating disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/035900
Other languages
English (en)
Other versions
WO2003039480A2 (fr
Inventor
Shutsung Liao
Ching Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Priority to CA002466033A priority Critical patent/CA2466033A1/fr
Priority to AU2002356919A priority patent/AU2002356919B2/en
Priority to EP02802882A priority patent/EP1450816A4/fr
Priority to JP2003541772A priority patent/JP2005508368A/ja
Publication of WO2003039480A2 publication Critical patent/WO2003039480A2/fr
Publication of WO2003039480A3 publication Critical patent/WO2003039480A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne une méthode destinée à traiter des troubles liés à un taux de cholestérol élevé. Cette méthode consiste à administrer à un sujet nécessitant un traitement un composé de formule (I). L'invention concerne également des procédés, des nécessaires, des combinaisons et des compositions qui sont utilisés pour traiter des troubles chez un sujet lorsqu'un activateur du récepteur alpha X du foie est indiqué, par exemple pour traiter une maladie liée à un taux de cholestérol élevé.
PCT/US2002/035900 2001-11-08 2002-11-08 Methode de traitement de troubles lies a un taux de cholesterol eleve Ceased WO2003039480A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002466033A CA2466033A1 (fr) 2001-11-08 2002-11-08 Methode de traitement de troubles lies a un taux de cholesterol eleve
AU2002356919A AU2002356919B2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration
EP02802882A EP1450816A4 (fr) 2001-11-08 2002-11-08 Methode de traitement de troubles lies a un taux de cholesterol eleve
JP2003541772A JP2005508368A (ja) 2001-11-08 2002-11-08 高コレステロール濃度に関連した疾患の治療方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08
US60/348,020 2001-11-08

Publications (2)

Publication Number Publication Date
WO2003039480A2 WO2003039480A2 (fr) 2003-05-15
WO2003039480A3 true WO2003039480A3 (fr) 2003-06-19

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035900 Ceased WO2003039480A2 (fr) 2001-11-08 2002-11-08 Methode de traitement de troubles lies a un taux de cholesterol eleve

Country Status (5)

Country Link
EP (1) EP1450816A4 (fr)
JP (1) JP2005508368A (fr)
CA (1) CA2466033A1 (fr)
TW (1) TW200300078A (fr)
WO (1) WO2003039480A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851457B2 (en) 2016-10-18 2023-12-26 Sage Therapeutics Oxysterols and methods of use thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (fr) 2004-10-25 2006-05-04 Virginia Commonwealth University Oxysterol sulfate nucleaire, regulateur homeostatique du cholesterol agissant puissamment dans le traitement de l'hypercholesterolemie, de l'hyperlipidemie et de l'atherosclerose
CA2585623C (fr) 2004-10-27 2012-06-05 Daiichi Sankyo Company Limited Derives de benzene substitue en position ortho
KR20090081020A (ko) 2006-11-13 2009-07-27 노파르티스 아게 Ｋｓｐ 억제제로서의 치환된 피라졸 및 트리아졸 화합물
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓ｘ受容体アゴニスト
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
RU2684103C2 (ru) 2013-03-13 2019-04-04 Сейдж Терапьютикс, Инк. Нейроактивные стероиды и способы их применения
CN119269811A (zh) * 2013-03-13 2025-01-07 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
JP2016193835A (ja) * 2013-09-04 2016-11-17 学校法人常翔学園 核内受容体肝臓ｘ受容体アゴニスト
MX377151B (es) 2013-12-24 2025-03-07 Us Dept Veterans Affairs Usos de sulfatos de colesterol oxigenados (soc).
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4609866A3 (fr) 2015-07-06 2025-10-22 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
WO2017007832A1 (fr) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
PL3319612T3 (pl) 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
RU2754130C2 (ru) 2016-04-01 2021-08-27 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3029900A1 (fr) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols et leurs methodes d'utilisation
CA3031224A1 (fr) 2016-08-02 2018-02-08 Shunlin Ren Compositions comprenant du 5-cholestene-3, 25-diol,3-sulfate (25 h3s) ou un sel pharmaceutiquement acceptable de celui-ci et au moins un oligosaccharide cyclique
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
TWI836485B (zh) 2016-10-18 2024-03-21 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
EP0562849A2 (fr) * 1992-03-27 1993-09-29 Eli Lilly And Company Dérivés de steroides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976857A (fr) * 1972-12-06 1974-07-24
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (ja) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
EP1189922A4 (fr) * 1999-04-30 2002-08-14 Arch Dev Corp Derives steroides
ES2296928T3 (es) * 2001-05-03 2008-05-01 The University Of Chicago Receptores x hepaticos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
EP0562849A2 (fr) * 1992-03-27 1993-09-29 Eli Lilly And Company Dérivés de steroides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCH. BIOCHEM. BIOPHYS., vol. 98, 1962, pages 305 - 311 *
DATABASE CAPLUS [online] WHITEHOUSE M. ET AL.: "Catabolism in vitro of cholesterol: some comparative aspects", XP002963337, accession no. STN Database accession no. 1962:464382 *
See also references of EP1450816A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851457B2 (en) 2016-10-18 2023-12-26 Sage Therapeutics Oxysterols and methods of use thereof

Also Published As

Publication number Publication date
TW200300078A (en) 2003-05-16
WO2003039480A2 (fr) 2003-05-15
JP2005508368A (ja) 2005-03-31
EP1450816A2 (fr) 2004-09-01
CA2466033A1 (fr) 2003-05-15
EP1450816A4 (fr) 2008-02-13

Similar Documents

Publication Publication Date Title
WO2003039480A3 (fr) Methode de traitement de troubles lies a un taux de cholesterol eleve
BR0114576A (pt) Composto, composição farmacêutica, uso de um composto, método de tratar um estado doentio e processo para preparar um composto
DE69512797D1 (en) Prostaglandin-synthase hemmer
WO2001052796A3 (fr) Procedes d'utilisation d'une composition de boisson
BR0316375A (pt) Diazinopirimidinas
NO20062292L (no) Fremgangsmate for behandling av transplantasjonsavstoting
ATE410400T1 (de) Verfahren zur herstellung von c13- alkoholgemischen
MXPA03011681A (es) Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
DE60024830D1 (de) Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
WO2005030120A3 (fr) Agents anti-angiogenese
WO2003024391A3 (fr) Traitement et prevention de la mucosite chez les patients cancereux
WO2003009803A3 (fr) Procede d'amelioration de la fonction cognitive
ATE250077T1 (de) Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
AU1185801A (en) Novel compounds
AU2003300385A1 (en) Anticancer compounds
WO2004024064A8 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
WO2003022280A3 (fr) 3-glyoxlylamide-indoles pour traitement du cancer
DE60202203D1 (de) Neues verfahren zur herstellung von oxabispidinen
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
WO2002014313A3 (fr) Nouveaux inhibiteurs de beta-amyloide, leurs procedes de production et leur utilisation comme medicaments
CA2421990A1 (fr) Acides .beta.-thioamines
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
DE602004009664D1 (de) Diclazurilhaltige antiprotozoenmittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2466033

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003541772

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002356919

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002802882

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002802882

Country of ref document: EP